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with no added sounds. The peripheral pulses were present,
equal, and symmetrical. No abnormalities were found in the
respiratory, abdominal, or nervous systems. She had no reti-
nopathy and ophthalmoscopy revealed normal fundi. Urinaly-
sis disclosed 3 blood and 1 protein.
Initial laboratory investigations demonstrated a serum creat-
inine of 513 mol/L (5.8 mg/dL); hemoglobin, 9.2 g/dL; and
normal white blood cell and platelet levels. Renal ultrasound
revealed two normal-sized kidneys. She was rehydrated with
normal saline, given a one-unit blood transfusion, and trans-
ferred to the Queen Elizabeth Hospital in Birmingham after
48 hours. At that point she was passing 1.0 to 1.5 liters urine/24 h
and her blood pressure was 170/100 mm Hg. Further laboratory
investigations demonstrated a serum creatinine of 317 mol/L
(3.6 mg/dL); BUN, 23 mmol/L; and serum albumin, 2.9 g/dL.
The hemoglobin level was 8.8 g/dL with normal indices. TheCASE PRESENTATION
erythrocyte sedimentation rate was 70 mm/hr. C-reactive pro-
A 62-year-old white woman presented to another hospital tein was 30 mg/L (normal 10 mg/L), and she had a positive
with a five-week history of profound malaise and small joint antineutrophil cytoplasmic antibody (ANCA) test to a titer of
arthralgia. Initially she had noticed a mild sore throat that set-
1:400 serum dilution by indirect immunofluorescence with a
tled spontaneously. She had transient redness of her left con-
perinuclear pattern. Subsequent antigen-specific ELISA con-junctiva. One week after the onset of symptoms, she had a
firmed reactivity to myeloperoxidase (MPO), denoting MPO-single episode of macroscopic hematuria for which she received
ANCA (Fig. 1). The ANA, anti-DNA, and anti-GBM antibodyantibiotics from her family doctor. She denied dysuria or uri-
tests were negative. Complement C3 and C4 levels were nor-nary frequency. For one week prior to admission, she had
mal, and cryoglobulins were not detectable. Hepatitis B andsuffered nausea and vomiting without abdominal pain or bowel
C serologies were negative. After control of blood pressure, adisturbance. She had lost one stone (14 pounds) in weight. She
renal biopsy was performed; the tissue contained eight glomer-had been hypertensive five years previously, but she had had
uli. Of these, one was globally sclerosed, three were normal,no other antecedent illnesses. There was no family history of
and four contained acute segmental lesions of various sizesrenal disease, hypertension, or rheumatic complaints. She had
with thrombosis, tuft disruption, and a few cells in Bowman’sfour adult children, all of whom were well. Medication on
space (Fig. 2). Tubules were acutely damaged, with blood inadmission comprised a beta blocker (atenolol, 100 mg daily)
a few. A patchy infiltrate of chronic inflammatory cells wasfor hypertension. She did not smoke cigarettes and drank less
present. Small arteries and arterioles appeared virtually nor-than three units (24 g) of alcohol per week. She was a poultry
mal. Immunoperoxidase study revealed no significant immuno-farmer and lived in a rural setting.
protein deposition within glomeruli.Clinical examination revealed that she was pale and dehy-
The clinical history, renal biopsy findings, and blood serologydrated. She had no rash, no active synovitis, and no lymphade-
were consistent with an acute vasculitic (pauci-immune) glo-nopathy. Her temperature was 37.2C; pulse, 70 beats/min;
merulonephritis of the microscopic polyangiitis type. An assess-and blood pressure, 160/90 mm Hg lying and 145/80 mm Hg
ment of vasculitic activity showed a Birmingham Vasculitis Ac-standing. Her jugular venous pressure was not elevated and she
tivity Score (BVAS) of 13 and a Vasculitis Damage Index (VDI)had no sacral or ankle edema. The heart sounds were normal
score of 0. Therapy with prednisolone, 1 mg/kg/day, and oral
cyclophosphamide, 2 mg/kg/day, was begun. Following 3 months
of therapy, her serum creatinine was 95 mol/L (1.1 mg/dL)
The Nephrology Forum is funded in part by grants from Amgen,
with a creatinine clearance of 87 mL/min. ANCA were noIncorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
longer detectable (Fig. 1). The BVAS score was 0, indicatingrated; and Bristol-Myers Squibb, Inc.
complete remission, and the VDI was 2, indicating a mild to
Key words: microscopic polyangiitis, Wegener’s granulomatosis, Churg- moderate degree of damage. The prednisolone dosage had
Strauss syndrome, crescentic glomerulonephritis been gradually reduced according to our local guidelines, and
at 3 months she was receiving 15 mg/day. The cyclophospha- 2001 by the International Society of Nephrology
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Fig. 3. Cortex in the patient’s second renal biopsy showing acute seg-
mental lesions in several glomeruli. PA silver 50.
Fig. 1. ELISA for MPO-ANCA showing serial antibody titers (EU/mL)
over time.
Fig. 4. Small artery in the patient’s second renal biopsy showing local-
ized destruction of the wall with acute inflammation. PA silver  250.
Fig. 2. Glomerulus in the patient’s first renal biopsy showing an acute and the C-reactive protein level was 37 mg/L. A nasal swab did
segmental lesion with thrombosis, disruption of capillary loops and not reveal carriage of Staphylococcus aureus, and although 6adhesion of the tuft to Bowman’s capsule. Periodic acid-methenamine
of 6 nasal swabs taken during the first 6 months of illness hadsilver (PA silver) 250.
been positive for this organism, later swabs had been negative.
A relapse of microscopic polyangiitis was suspected. She was
admitted to the hospital and a second renal biopsy was per-
formed. The specimen contained 15 glomeruli, one globallymide dose had been maintained throughout, as there had been
sclerosed, one with a small old area of capsular adhesion, 5no episodes of leukopenia (white blood cell count 4.0 
normal, and 8 with segmental lesions of various sizes showing109/L). As she was in remission, cyclophosphamide was discon-
thrombosis, tuft disruption, and a few cells in Bowman’s spacetinued and azathioprine was commenced at 2 mg/kg/day. She
(Fig. 3). The tubules appeared acutely damaged, with blood inremained well with no clinical evidence of vasculitic activity, a few and some patchy atrophy. Interstitial tissues were edema-
and 18 months from diagnosis (15 months from the time of tous and contained a patchy inflammatory infiltrate. Small ar-
remission) her therapy was prednisolone, 5 mg/day, and azathi- teries and arterioles had chronic intimal thickening. One small
oprine, 100 mg/day. In addition, she was receiving three agents artery contained a patch of fibrinoid necrosis (Fig. 4). Immuno-
for control of hypertension, calcium and vitamin D tablets (later peroxidase staining showed no significant deposition of immu-
changed to Didrone PMO), and an H2 receptor antagonist. noproteins in the glomeruli. Features were those of reactivation
At 17 months (500 days), MPO-ANCA again was detectable of severe renal vasculitis, both acute vasculitic glomerulone-
in the serum (Fig. 1). Therapy was not altered because there phritis and an acute arteritis. Daily oral cyclophosphamide and
was no clinical evidence of vasculitis, urinalysis showed 1 prednisolone were begun as previously. Within 10 weeks, the
protein, renal function was stable, and the C-reactive protein BVAS score was 0, urinalysis was negative for blood and pro-
tein, serum creatinine had returned to 96 mol/L (1.1 mg/dL),level was 10 mg/L. She remained under review in the clinic.
C-reactive protein was 10 mg/L, and ANCA were no longerShe was well until 44 months following her acute illness,
detectable in the serum.when she presented to the renal vasculitis outpatient clinic with
a 4-week history of fatigue, upper respiratory tract symptoms of
coryza and a sore throat, and new episcleritis. The BVAS score DISCUSSIONhad risen to 8. Urinalysis revealed 3 blood and 1 protein.
Dr. Caroline O. S. Savage (Professor of Nephrology,The serum creatinine had risen to 125 mol/L (1.4 mg/dL).
The MPO-ANCA titers had risen further (Fig. 1;1320 days), MRC Centre for Immune Regulation, and Division of Med-
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ical Sciences, The Medical School, The University of Bir- studies which I will discuss later. The definitions for these
three entities appear in Table 1.mingham, United Kingdom): The patient today is typical
of many with ANCA-associated renal vasculitis of the A vascular pathology is shared among these three dis-
orders. Focal necrotizing lesions are the common vascu-microscopic polyangiitis type. The presenting signs of sys-
temic disease were subtle, but the marked fatigue, arthral- lar pathology that characterizes these three disorders.
These lesions can affect many different vessels and leadgia, and episcleritis attest to the systemic nature of micro-
scopic polyangiitis. In fact, the presentation of this patient to a variety of symptoms and signs. For example, involve-
ment of glomerular capillaries causes nephritis, of alveo-is almost identical to that of Patient 1 presented by Dr.
Ronald Falk in the last Nephrology Forum to consider lar capillaries causes lung hemorrhage, of epineural ar-
teries causes mononeuritis multiplex, and of dermalvasculitis, 11 years ago [1]. That patient had cANCA
with reactivity towards proteinase 3 by ELISA, denoting venules causes purpura. In the kidney, early glomerular
lesions have focal segmental necrosis of capillary loopsPR3-ANCA. At the time there was uncertainty as to the
spectrum of ANCA-associated vasculitides, and three with some thrombosis and neutrophil infiltration; with
progression, mononuclear cells are recruited, and breakstypes were proposed. Patient 1 was given the diagnostic
label “polyarteritis nodosa”; the other two suggested in the glomerular basement membrane quickly lead to
crescent formation [4, 5]. The acute lesions evolve intotypes of ANCA-associated vasculitis were Wegener’s
granulomatosis and “idiopathic” crescentic glomerulo- sclerotic lesions. Immunohistology shows little deposi-
tion of immune reactants; this feature distinguishes le-nephritis. The question of specificity of cANCA for Weg-
ener’s granulomatosis was raised, given that Patient 1 did sions due to ANCA-associated vasculitis from those of
antiglomerular basement membrane disease, IgA ne-not fulfill the diagnostic criteria developed by Godman
and Churg in the 1950s [2]. In the intervening 11 years phropathy, and lupus nephritis. Patients with Wegener’s
granulomatosis and Churg-Strauss syndrome have addi-since Falk’s Forum, diagnostic criteria have been put for-
ward by the Chapel Hill International Consensus Confer- tional granulomatous necrotizing lesions, with areas of
necrosis surrounded by mixed infiltrates of neutrophils,ence [3], large multinational studies have been under-
taken to examine the sensitivity and specificity of ANCA lymphocytes, monocytes, macrophages, and scattered
multinucleate giant cells. These necrotic areas are foundfor vasculitis, and three ANCA-associated vasculitides
have become widely recognized, namely Wegener’s granu- most often in the respiratory tract and are separate from
“granuloma-like” structures that can develop in the kid-lomatosis, microscopic polyangiitis, and Churg-Strauss syn-
drome. Nowadays Patient 1 would be considered typical ney from periglomerular infiltrates located around in-
volved glomeruli. Eosinophils are very conspicuous inof microscopic polyangiitis. A variety of descriptive labels
have been applied to this vasculitis limited to the kidney, the lesions of Churg-Strauss syndrome.
The relative rarity of vasculitis, the lack of clear defini-including idiopathic, crescentic, and pauci-immune, and
the disorder is now recognized for its propensity to pro- tions, and the overlap among syndromes have made the
collection of epidemiologic data difficult [reviewed in 6].gress to systemic microscopic polyangiitis or Wegener’s
granulomatosis if untreated [4]. In the 1970s, the overall annual incidence for all forms
of systemic vasculitis occurring in the west of England
Defining ANCA-associated vasculitis was 10/million. Data collected in Leicester, United King-
dom in 1980 to 1986 and 1987 to 1989 suggested the com-The International Consensus Conference in 1994 made
an important attempt to clarify the nomenclature for bined annual incidence of Wegener’s granulomatosis and
microscopic polyangiitis to be 1.5/million and 6.1/million,vasculitis, attaching definitions to the major recognized
syndromes to facilitate international understanding and respectively. In the United States over a similar period
(1979 to 1988), the prevalence of Wegener’s granuloma-awareness [3]. Definitions were provided for giant cell
arteritis, Takayasu arteritis, polyarteritis nodosa, Kawa- tosis was approximately 30/million. During 1988 to 1998,
the overall incidence of ANCA-associated vasculitidessaki disease, Wegener’s granulomatosis, microscopic poly-
angiitis, Churg-Strauss syndrome, Henoch-Scho¨nlein was 21.5/million within the Norwich area in east England.
During 1988 to 1992 and 1993 to 1998, the incidencepurpura, cryoglobulinemic vasculitis, and cutaneous leu-
kocytoclastic angiitis. Three diseases, Wegener’s granu- was 17.4/million and 23.8/million, respectively; this rate
suggests an increased incidence of ANCA-associatedlomatosis, microscopic polyangiitis (acquiring clear dis-
tinction from polyarteritis nodosa and with the preferred vasculitis. Studies from Norway suggest a doubling inci-
dence of Wegener’s granulomatosis from 1992-1994 toterm “microscopic polyangiitis” over “microscopic poly-
arteritis”), and Churg-Strauss syndrome, were acknowl- 1995–1998. These figures probably reflect a real increase
in incidence as well as improved awareness and diagno-edged to be “commonly associated with ANCA.” The
association of Wegener’s granulomatosis, microscopic po- sis. A very high incidence of microscopic polyangiitis
(24/million) is seen in Kuwait.lyangiitis, and Churg-Strauss syndrome with ANCA has
been backed up by several large, including multinational, Vasculitides must be recognized early if successful
Nephrology Forum: ANCA-associated renal vasculitis 1617
Table 1. Diseases commonly associated with ANCA
Wegener’s granulomatosis Granulomatous inflammation involving the respiratory tract, and necrotizing vasculitis affecting small- to
medium-sized vessels (e.g., capillaries, venules, arterioles, and arteries). Necrotizing glomerulonephritis
is common.
Microscopic polyangiitis Necrotizing vasculitis with few or no immune deposits affecting small vessels (i.e., capillaries, venules, or
arterioles). Necrotizing arteritis involving small and medium-sized arteries can be present. Necrotizing
glomerulonephritis is very common. Pulmonary capillaritis often occurs.
Churg-Strauss syndrome Eosinophil-rich and granulomatous inflammation involving the respiratory tract, and necrotizing vasculitis
affecting small- to medium-sized vessels; associated with blood eosinophilia and usually asthma or other
form of atopy.
Modified with permission from Jennette et al [3].
treatment is to be implemented. ANCA-associated vas- cases of Wegener’s granulomatosis have been reported
in pregnant women. The pregnancies were successfulculitides can occur at any age, including in children and
the elderly; the peak occurrence is in the 55- to 70-year and little evidence indicates transfer of disease to the
fetus [reviewed in 11]. The cause of fetal death in twoage group [6]. Early diagnosis is important for reducing
the ability of acute vasculitis to cause death from major reported spontaneous abortions was not provided.
Indirect evidence includes presence of autoantibodiesorgan failure, for example, respiratory failure from pul-
monary hemorrhage, and to reduce major long-term or self-reactive T-cells in the target organs or lesions of
the disease, or reproduction of autoimmune disease inmorbidity, for example, end-stage renal failure. As in
our patient at the time of her relapse, severe, biopsy- experimental animal models. ANCA-associated vasculi-
tides have long been associated with a lack of immuno-proven disease can be accompanied by apparently mild
clinical organ involvement. Our patient’s serum creati- globulin deposition in lesions [4]. CD4 and CD8
T-cells, present in lesions, are predominantly of thenine was 1.4 mg/dL.
CD45RO memory phenotype, but their antigen specific-
Causes ity is unknown [12]. Antigen-specific, PR3- or MPO-
reactive T-cells have been detected in the peripheralAlthough the causes of ANCA-associated vasculitides
are unknown, the presence of ANCA suggests an auto- blood of patients with ANCA-positive vasculitis [13, 14].
A common dominating T-cell receptor BV8-F/L-G-G-immune basis. Witebsky and colleagues used modifica-
tions of Koch’s postulates, which had been developed A/Q-G-J2S3  chain sequence was found in CD4
T-cells from four unrelated patients with vasculitis, allto establish the pathogenicity of a transmissible agent,
to define an autoimmune etiology for a disease [7]. Thus, of whom were HLA-DRB1*0401 allele positive; this
finding suggested that all four patients had been exposedan autoantibody or cell-mediated immune response is
required, the corresponding antigen must be identified, to, and elicited a cell-mediated immune response against,
a common antigen [15].an analogous autoimmune response must be induced in
experimental animals, and the immunized animal must Attempts have been made to reproduce vasculitis in
experimental animals [reviewed in 16]. Brown-Norwaydevelop similar disease. Rose and Bona identified direct,
indirect, and circumstantial evidence that supports an rats immunized with human MPO develop antihuman
MPO antibodies that cross-react with rat MPO, but vas-autoimmune cause for ANCA-associated vasculitis [8].
Direct evidence includes transfer of patient serum, culitis does not develop. However, rats subsequently sub-
jected to other manipulations such as renal perfusionpurified immunoglobulin, or autoantigen-specific T-cells
to experimental animals, or transplacental transfer of of neutrophil lysosomal extract (consisting primarily of
MPO) followed by either H2O2 perfusion or clamp isch-pathogenic IgG. For ANCA-associated vasculitides, di-
rect evidence of autoimmunity is lacking. Retinal vasculi- emia, develop a crescentic necrotizing glomerulonephri-
tis. Attempts at reproducing this animal model have re-tis has been reported in a single individual after intrave-
nous human immunoglobulin containing ANCA was sulted in significant immune complex deposition, but the
original observations, together with an ability of circulat-used for treatment of a nonvasculitic condition [9], but
in other studies intravenous immunoglobulin has been ing anti-MPO antibodies to aggravate subnephritogenic
anti-glomerular basement membrane (GBM) disease inused successfully to treat ANCA-associated vasculitis
[10]. There has been no documentation of transferred rats, suggest that anti-MPO antibodies could have patho-
genic co-factor potential. That MPO-ANCA alone areANCA inducing disease in experimental animals, analo-
gous to the induction of glomerulonephritis in squirrel insufficient to induce vasculitis is also suggested by stud-
ies with SCG/Kj mice derived from BXSBx MRL/Mp-monkeys after injection of antiglomerular basement
membrane antibodies eluted from the kidneys of patients lpr/lpr F1 hybrid mice. These mice develop a crescentic
glomerulonephritis together with anti-MPO antibodieswho had died from Goodpasture’s disease. About 20
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that can bind to murine neutrophils. However, transfer an autoimmune process. Untreated, vasculitis carries a
very poor prognosis. In early studies, Wegener’s granulo-of MPO-specific hybridomas induces proteinuria but no
vasculitis or nephritis. Thus, even if MPO and neutrophils matosis carried a 90% two-year mortality rate [26]. Mor-
tality data for untreated microscopic polyangiitis are notare necessary for development of vasculitis, they are not
sufficient to induce it. Other experimental models such available, because early studies contained heterogeneous
vasculitides including polyarteritis nodosa. Cytotoxicas mercuric chloride (HgCl2)-induced vasculitis or spon-
taneous vasculitis in autoimmune MRL/lpr mice do not therapy using cyclophosphamide together with cortico-
steroids induces remission in more than 90% of patientstruly replicate human ANCA-associated vasculitides, ei-
ther in terms of clinical course or pathology, whereas the [27]. In addition, a role for cell-mediated immunity in
systemic vasculitis is suggested by beneficial responsesANCA develop as part of a polyclonal antibody response.
Attempts at developing PR3-ANCA-associated vasculitis of some patients to treatment with monoclonal anti-T-
cell antibodies (CD4, CD52) [28].have largely been unsuccessful, mainly because of the poor
homology between rodent and human PR3. Altogether, Clustering of autoimmune diseases provides further
support for the autoimmune basis of each individualperhaps the most important observation from the animal
models is that ANCA alone are not pathogenic. Addi- disorder. Concurrence of anti-GBM disease and ANCA-
associated vasculitis is recognized [29]. In one study,tional factors inducing priming or activation of neutro-
phils, monocytes, or vascular endothelial cells are re- ANCA occurred in 38 of 100 patients with anti-GBM
antibodies [30]. At present this clustering cannot be ex-quired, after which the inflammatory process can be
exacerbated by ANCA-neutrophil-endothelial cell inter- plained through major histocompatibility complex (MHC)
associations. Anti-GBM disease is strongly associatedactions, and perpetuated by T-cells and monocytes.
Circumstantial evidence includes association of auto- with HLA-DRB1*1501 (a DR2 allele), and this associa-
tion lends strong support to the occurrence of cell-medi-immune mediators such as autoantibody with disease
activity, association with other autoimmune diseases, ated immune responses, but MHC associations have
been more difficult to discern for the ANCA-associatedlymphocytic infiltration in target organs, major histocom-
patibility complex class-II associations, and response to vasculitides. The literature contains conflicting reports of
positive associations with, among others, HLA-B8, -DR2,immunosuppression. Considerable circumstantial evi-
dence suggests an autoimmune cause in the three ANCA- and -DQw7; negative associations with DR13DR6; or a
lack of association [reviewed in 31].associated vasculitides.
A strong association exists between vasculitis and the In short, good circumstantial evidence supports the
autoimmune nature of systemic vasculitis associated withpresence of ANCA. Recent large multicenter studies com-
bining immunofluorescence and enzyme immunoassays ANCA. A small proportion of patients remain ANCA-
negative. Some of these patients might not have truehave demonstrated a specificity approaching 99% for Weg-
ener’s granulomatosis, microscopic polyangiitis, or their vasculitis. For example, TAP deficiency with an associ-
ated reduced MHC class-I expression on leukocytes hasrenal-limited variant [17, 18]. In a single-center study of
123 patients with Wegener’s granulomatosis or micro- been described recently in a group of patients with a
Wegener-like condition [32].scopic polyangiitis, ANCA positivity was 97% according
to indirect immunofluorescence and ELISA, the newer An association has been noted between the anti-
thyroid drug propylthiouracil and the development ofcapture-ELISA technique [19]. In a meta-analysis of
cANCA testing in Wegener’s granulomatosis, the pooled ANCA-associated vasculitis [reviewed in 33]. This corre-
lation has led to the intriguing suggestion that MPO,sensitivity was 91% (CI, 87% to 95%) and the pooled
specificity was 99% (CI, 97% to 99.9%) for the subset which is involved in the formation of reactive metabolites
from propylthiouracil, binds covalently to one of the me-of patients with active disease, compared with 63% (CI,
57% to 69%) and 99.5% (CI, 99.1% to 99.7%) for those tabolites to form an immune complex. If the metabolite
then acted as a hapten, ANCA formation might be in-with inactive disease, where confidence intervals are
given [20]. Methodologic discrepancies and flaws might duced in genetically susceptible individuals. Thus, auto-
immunity to ANCA antigens could result from modifiedhave diluted the association between ANCA and its asso-
ciated vasculitides in earlier studies. self. Other drugs associated with ANCA-positive vasculi-
tis include hydralazine and penicillamine. A number ofThe correlation of ANCA titers with clinical disease
activity supports an autoimmune cause and direct patho- cases of Churg-Strauss syndrome have been reported
following the introduction of leukotriene receptor antag-genicity of ANCA [21, 22]. Further, in one study, disease
relapse could be predicted and prevented by intensifying onists. It remains unclear whether vasculitis is secondary
to the drug or whether the drug permits a reductionimmunosuppression in response to rising titers [23]. Per-
sistent or intermittent ANCA positivity is an indepen- of steroid dose and the manifestation of latent Churg-
Strauss syndrome [34]. Each view has its protagonists.dent risk factor for relapse [24, 25].
Disease response to immunosuppression also supports Case-controlled studies are lacking.
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Infectious agents have long been suspected of playing (Fig. 5). Neutrophils from patients with active vasculitis
exist in a primed or pre-activated state, with increaseda role in the development of the vasculitides. Strong
expression of CD66b, CD64, and CD63, together withevidence indicates a hepatitis B viral cause in some cases
PR3, on the cell surface [39, 40]. ANCA IgG bind theof polyarteritis nodosa and for hepatitis C in cryoglobu-
surface-expressed antigens via their F(ab)2 portions andlemia. In ANCA-associated vasculitis, evidence conflicts
trigger neutrophil activation by ligation of constitutivelyconcerning the seasonal incidence; some reports suggest
expressed Fc	 receptors, Fc	RIIa and Fc	IIIb [41-43];that the onset of symptoms is more common in winter.
some signaling also can occur following antigen ligationChronic nasal carriage of Staphylococcus aureus appears
by ANCA F(ab)2 [44]. This antigen binding results ina significant risk factor for disease relapse in Wegener’s
intracellular signaling cascades that include tyrosinegranulomatosis [25], and results of a European Vasculitis
phosphorylation, PKC translocation, and PI 3-kinase ac-Study group (EUVAS) trial to confirm or refute this
tivation, but not phospholipase D activation (abstract;association are awaited. That patients carrying superanti-
Ben-Smith et al, J Am Soc Nephrol, 10:570A, 2000) [43].gen-positive staphylococcal strains seem at particular
Signal transduction activates a respiratory burst with therisk suggests a role for staphylococcal enterotoxins as
release of reactive oxygen species and leukotrienes, de-superantigens in disease induction [35]. Cotrimoxazole
granulation of azurophilic granules, and secretion of pro-
therapy might have beneficial effects on control of dis-
inflammatory cytokines [45-48]. Adhesion via 2 integ-
ease activity and possibly reduces relapse rates [36], but rins is also required for neutrophil activation by ANCA
whether this occurs via effects on S. aureus or via other [49], and might be involved in ANCA’s ability to convert
immunomodulatory activities remains to be determined. neutrophil rolling adhesion to firm adhesion [50].
An association between ANCA-associated vasculitis ANCA also induce accelerated neutrophil apoptosis.
with renal involvement and silica exposure has been re- This process depends both on prior priming with TNF

ported in three small case-control studies, with odds ra- and on neutrophil activation with a resultant respiratory
tios between 6 and 12 [reviewed in 37]. However, a more burst, as accelerated apoptosis is not seen in the presence
recent case control study of renal and nonrenal Wegen- of catalase or with neutrophils from individuals with
er’s granulomatosis did not confirm this association [38]. chronic granulomatous disease that lacks NADPH oxi-
Further studies are required to confirm or refute this dase [51]. However, the accelerated apoptosis has some
association and also to determine the role, if any, of hy- unusual features. The ANCA-induced apoptosis is dys-
drocarbon exposure. regulated: the morphologic changes of apoptosis develop
without accelerated surface expression of phosphatidyl-
Are ANCA pathogenic? serine, necessary for successful clearance of such apo-
ptotic cells by scavenging phagocytes. Failure to clearA number of careful clinical studies have suggested,
these neutrophils in vivo can result in progression toas I already mentioned, that ANCA contribute to the
secondary necrosis (Fig. 5) and lead to the intravascularpathogenesis of vasculitis. At the last Nephrology Forum
leukocytoclasis that typifies vasculitic lesions.on vasculitis, in 1990, Dr. Falk noted that ANCA could
How might these effects relate to endothelial injury?induce live neutrophils to degranulate and undergo a
In vitro, neutrophil activation by ANCA can cause endo-respiratory burst [1]. At the time, evidence suggested
thelial cell injury and can convert neutrophil rolling ad-that cytokine priming of neutrophils allowed externaliza-
hesion to firm adhesion [50] and can cause endothelialtion of the target antigens to the cell surface to facilitate
cell injury [52]. Stimulation of neutrophils by IL-8, se-this process. Ten years on, the premise that ANCA acti-
creted by monocytes and neutrophils in response tovate cytokine-primed neutrophils has stood the test of
ANCA [53, 54], produces rapid actin cytoskeletal reorga-
time. Our understanding of how neutrophils are acti-
nization and can inhibit neutrophil transendothelial mi-
vated has advanced, the idea has emerged that neutro- gration [55]. TNF
 down-regulates the expression of the
phils are not only activated but that function is dysregu- IL-8 receptor CXCR2, but not CXCR1, and thus reduces
lated, and ANCA have been found to alter the apoptotic the ability of neutrophils to respond to an IL-8 chemotac-
rate of primed neutrophils and to interact with neutro- tic gradient while increasing superoxide release, which
phils already undergoing apoptosis. An attempt has been is mediated by CXCR1 [56]. Collectively, these effects
made to understand how these interactions between could result in intravascular retention of neutrophils. In
ANCA and neutrophils contribute to the development vivo, this intravascular retention might lead to delayed
of the earliest lesions of vascular injury. migration or even trapping of neutrophils within capil-
In vitro studies have shown that priming of neutrophils lary circulatory systems such as the glomerulus. Increased
with cytokines such as TNF
, TGF, or IL-8 leads to neutrophil-endothelial adhesion can increase the local-
the translocation of both MPO and PR3 to the neutrophil ization of activated neutrophils to endothelial cells [50].
Reactive oxygen species, cytokines, proteolytic enzymes,surface, where they are available for ANCA binding
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Fig. 5. Stages in the initiation and develop-
ment of vasculitic lesions. (A) Production of
high-affinity ANCA IgG from plasma cells.
The events leading to this are unclear but are
likely to require T-cell help within lymphoid
tissues. (B) Circulating neutrophils (PMN) and
vascular endothelial cells (EC) are in a resting
(r) state until: (C ) infection leads to local gen-
eration of cytokines such as TNF
, which prime
neutrophils (pPMN) to surface-express PR3
or MPO [ ] and induce endothelial cell activa-
tion (AcEC); (D) ANCA bind and activate
neutrophils (AcPMN) following engagement
of antigen [by F(ab)2] and Fc	R (by Fc). PMN
become adherent with EC through adhesion
molecule interactions. Release of reactive ox-
ygen radical and inflammatory mediators (cy-
tokines, proteases→) from PMN and EC initi-
ates endothelial damage. Anti-endothelial cell
antibodies may contribute to EC activation.
(E ) Released IL-8 causes delay of PMN mi-
gration and/or retention of AcPMN within the
microcirculation. Primed PMN undergo accel-
erated apoptosis in response to ANCA and
progress to secondary necrosis (nPMN) within
the microcirculation. Intravascular thrombo-
sis and EC necrosis develop (nEC). PR3 bind-
ing to EC may contribute. Amplification of
inflammation follows recruitment of mononu-
clear cells (monocytes, T-cells) into lesions.
myeloperoxidase, nitric oxide, and secondary neutrophil teract with ANCA and increase injury [reviewed in 31].
Further, the endothelium can contribute to injury bothnecrosis all might contribute to directly damaging the
endothelial cell [reviewed in 31]. That the earliest vascu- by increasing its adhesive and prothrombotic properties
in response to cytokines and by acting as a target forlitic lesions are thrombotic, necrotic, contain small num-
bers of neutrophils, and are associated with the presence binding of ANCA antigens [reviewed in 31]. Both PR3
and MPO can bind to endothelial cells; indeed, specific re-of lysed leukocytes within the vessels [57] is consistent
with the activity of such mechanisms. Further, the num- ceptors for PR3 can be present on endothelial cells [60].
ANCA binding to these surface-expressed antigens can in-ber of activated neutrophils in vasculitic renal biopsies
correlates with the degree of renal impairment, as as- duce endothelial cell cytotoxicity [61], MPO-induced de-
tachment [61], and PR3-induced apoptosis [62]. Contrarysessed by serum creatinine [58], while activated neutro-
phils are present within the circulation, and their extent to initial reports [63], endothelial cells do not express
PR3 and hence are not direct targets for PR3-ANCAof activation, as measured by surface expression of PR3,
correlates with disease activity [59]. [60, 64, 65]. However, the presence of anti-endothelial
cell antibodies in some patients might contribute to en-Monocytes, known to express MPO and PR3, can in-
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dothelial activation [66]. Such endothelial activation or corticosteroids and cyclophosphamide. Combined ther-
apy will induce remission in more than 90% of patientsinjury could precede and promote the vasculitic lesions.
Proteinase 3 and MPO also are expressed on neutro- [27]. The details of the dose, route, and duration of ther-
apy vary. A commonly used approach is prednisolone com-phils undergoing apoptosis [67]. Pro-inflammatory re-
sponses can follow from the presence of ANCA antigens mencing at 1 mg/kg/day (to a maximum of 80 mg), reduc-
ing to 10 mg/day by 3 months [71]. Cyclophosphamideon the surface of apoptotic neutrophils, as opsonization
of these cells by ANCA increases their uptake by macro- has advocates for both daily oral and intermittent pulse
regimens. Many nephrologists use 2 mg/kg/day, adjustedphages [40]. Macrophage phagocytosis of opsonized
apoptotic cells stimulates further inflammatory cytokine for age and renal function, for three months, provided
the white blood cell count remains above 4  109/L. Thisrelease by macrophages, including TNF
, and leads to
persistence of the inflammatory reaction and further tis- approach is supported by the preliminary results from
CYCAZAREM, a European collaborative, prospective,sue damage.
As association between a deficiency of 
1-antitrypsin, randomized controlled trial examining the benefit of us-
ing azathioprine instead of cyclophosphamide for main-the main inhibitor of proteinase 3, and PR3-ANCA-posi-
tive vasculitis suggests that the neutrophil-ANCA-pro- taining remission [72]. It has been suggested that intra-
venous pulse cyclophosphamide therapy is associatedteinase 3 loop is an important determinant of tissue injury
in vasculitis. The PiZ allele, which codes for a nonsecreted with a lower cumulative dosage and fewer adverse ef-
fects, but clinical trials are required to confirm this andform of the inhibitor, is associated with severe disease
and poor prognosis [68]. Polymorphisms in Fc	 receptors to determine the relative effectiveness of intermittent
pulse versus daily oral therapy on control of diseasebound by ANCA on the surface of neutrophils and mono-
cytes also have been studied in view of their potential activity. Unfortunately, existing randomized prospec-
tive controlled trials do not provide a definitive answer.effects on neutrophil activation by ANCA. We have not
found associations between the development of ANCA- When the plasma creatinine at presentation is greater
than 500 mol/L (5.7 mg/dL), I believe that one shouldassociated vasculitis and alleles of FccRIIa (H131, R131)
or FccRIIIb (NA1, NA2) [69, 70]. However, patients with escalate therapy by adding intravenous pulses of methyl-
prednisolone, 15 mg/kg (maximum 1 g) for three days,vasculitis are more likely to develop renal failure if they
have the FccRIIa-R131 allele [69]. or by commencing a course of seven 3-liter plasma ex-
changes. Intravenous immunoglobulin also has beenWhile substantial evidence exists that ANCA contrib-
ute to initiation and early pathogenesis of vascular dam- used during induction of remission, but its efficacy has
not been tested in prospective controlled trials.age, the questions of how they develop in the first place
and why tolerance is lost to PR3 and MPO remain. Since The choice of maintenance therapy has to be balanced
between the risks of disease recurrence (which vary be-ANCA are high-affinity, IgG subclass-switched antibod-
ies, it is reasonable to presume that memory B-cells have tween 25% and 50% over the first 3 to 5 years) and toxicity
of therapy. One approach is to substitute azathioprinedeveloped in germinal centers with T-cell help as part
of a secondary immune response. During the late stages for cyclophosphamide after the first 3 to 6 months, while
reducing the prednisolone to very low levels or discontinu-of vasculitic injury, ANCA contribute little, being over-
shadowed by monocyte/macrophages and T-cells that ing it altogether [71]. Alternatives to azathioprine include
methotrexate [73], although this drug is contraindicatedare recruited to lesional sites [12].
if the serum creatinine is 2 mg/dL, or mycophenolate
Therapy mofetil [74]. At present it is unclear whether continua-
tion of azathioprine beyond 18 to 24 months helps reduceUntreated, the prognosis of ANCA-associated vasculi-
tis with renal involvement is poor, with few patients the long-term likelihood of relapse. Trimethoprim-sulfa-
methoxazole also can be useful in reducing the risk ofsurviving past one year. Current immunosuppressive reg-
imens allow survival rates of greater than 80% at one relapse during maintenance therapy [36], perhaps in as-
sociation with immunosuppressive therapy.year. The greatest threat comes from acute pulmonary
hemorrhage, which carries a high mortality. Patients with vasculitis require 3-month review over
the long term to detect early signs of disease recurrence.Treatment needs to be tailored to the different stages
of disease and can be divided into therapy to induce Some evidence indicates that patients are more likely to
relapse if ANCA reappear in the circulation or if thereremission, maintain remission, or treat relapse. One also
should tailor therapy to the severity and extent of dis- is a sustained rise in ANCA titers [22, 24]. Therapy for
relapse depends on its severity and the time at whichease; non-renal Wegener’s granulomatosis, presence of
renal disease, or disease with life-threatening pulmonary the relapse occurs relative to therapy for the vasculitis.
Thus, choice of therapy will vary between an increasehemorrhage need different approaches. I will focus here
on patients with renal involvement. in corticosteroid dosage to reinstitution of a full course
of corticosteroid and cyclophosphamide therapy.Induction-of-remission therapies require high-dose
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It is always important to distinguish tissue damage have excluded an association of the promoter polymor-
phism TNF-303 with ANCA-associated vasculitis, how-caused by active vasculitis from that caused by non-
healing scars inflicted by the disease itself or by toxic ever [78, 79]. This exclusion suggests that factors control-
ling TNF
 production differ between vasculitis andtreatment. Only acute disease is amenable to immuno-
suppressive therapy. Tools have been designed to help rheumatoid arthritis.
Prof. John Saville (Professor of Medicine, Centre forthe clinician with the assessment of acute disease and
tissue damage. As we saw in the case presentation, the Inflammation Research, Royal Infirmary, Edinburgh, Scot-
land): You have emphasized the role of oxidant stressBirmingham Vasculitis Activity Score (BVAS) is a vali-
dated scoring system for assessing disease activity solely in promoting tissue injury in ANCA-associated disease.
Given that antioxidants such as vitamin E confer benefitdue to vasculitis [75]. It can be used to monitor patients,
evaluate their responses to therapy, and screen for re- in atheromatous disease—in which oxidative stress, en-
dothelial injury, and dysregulated apoptosis are promi-lapse. Other scoring systems include the Vasculitis Activ-
ity Index, the Disease Extent Index, and the Groningen nent—is there any evidence that antioxidants might be
of benefit, particularly in the problematic area of mainte-Vasculitis Score [reviewed in 76]. The Vasculitis Activity
Index suffers from the disadvantage that it does not nance therapy after remission of vasculitis has been in-
duced?differentiate chronic from acute damage. The Disease
Extent Index (ELK, standing for ear, nose, throat, lung, Prof. Savage: Dr. Lorraine Harper in our group per-
formed a small pilot study. She looked at oxygen radicaland kidneys) was limited in its scope but has now been
extended to include additional organs. The Groningen production from neutrophils from patients in remission
who had no evidence of disease activity, although theyVasculitis Score was designed for use only in Wegener’s
granulomatosis and has the disadvantage that the assess- were still receiving low doses of prednisolone and azathi-
oprine. She found that their baseline superoxide produc-ment requires a biopsy, thus limiting its use. The Vasculi-
tis Damage Index (VDI), which aims to provide informa- tion was still greater than that of normal controls. She
then gave the patients 10 days of vitamin C and vitamintion on chronic damage, scores the accumulation of
E treatment and re-measured the superoxide productionnonhealing scars due to effects of disease (for example,
from neutrophils; it had fallen to normal levels. This isend-stage renal failure) or therapy (for example, infertil-
interesting for two reasons. First, the decrease suggestsity due to cyclophosphamide) [75]. Over time, the VDI
that even when patients are in clinical remission, theyscore will stay the same (if there is no further damaging
are not totally normal. That notion is also supported by,event) or increase if the patient continues to suffer fur-
for example, elevated von Willebrand factor levels thatther tissue-damaging events.
persist during clinical remission. Second, the vitamin CWhat of patients with end-stage renal failure? Provid-
and vitamin E study suggests that it is possible to modifying the disease is in remission, there is no contraindica-
neutrophil oxidant production.tion to transplantation, even if ANCA are still detectable
Prof. Andrew Rees (Department of Medicine andin the serum. Evidence suggests a low relapse rate in pa-
Therapeutics, University of Aberdeen, Institute of Medicaltients with functioning transplants, and relapses often can
Sciences, Aberdeen, Scotland): One of the really strikingbe effectively treated by utilizing cyclophosphamide [77].
things about the ANCA-associated diseases is the bias
in the clinical phenotype that is associated with the par-
QUESTIONS AND ANSWERS ticular ANCA specificities, PR3 with granulomatous dis-
Dr. John T. Harrington (Dean, Tufts University ease and MPO with vasculitis without granulomas. Why
School of Medicine, Boston, Massachusetts, USA): Cyto- should that be the case?
kines are ubiquitous and tumor necrosis factor is al- Prof. Savage: Microscopic polyangiitis splits more or
leged to be involved both in rheumatoid arthritis and less equally between PR3-ANCA and MPO-ANCA
Wegener’s granulomatosis. What “tells” TNF to attack without any obvious difference in the phenotype. So
the joints in rheumatoid arthritis and the kidneys in to consider that PR3-ANCA associate with granuloma
Wegener’s? formation might be misleading. However, disease induc-
Prof. Savage: I think that the tumor necrosis factor tion might take different routes. In Wegener’s, a nasal
in these diseases is initiating or amplifying injury in the mucosal factor might initiate disease associated with spe-
presence of co-factors that might be site- or disease- cific cytokine profiles and associated with the early gran-
specific. Local TNF
 production is increased in renal uloma. As the Wegener’s evolves, it becomes more vas-
biopsies of ANCA-associated glomerulonephritis, and culitic and systemic with development of PR3-ANCA;
TNF
 concentrations correlate with disease activity. In in other words, it becomes more like microscopic polyan-
some inflammatory disorders, including rheumatoid ar- giitis. Interestingly, we have found that IgG from MPO-
thritis, the TNF-303 (A) allele of the promoter has been ANCA-positive patients are more activating than are
IgG from PR3-ANCA-positive patients [80]. Our resultsassociated with increased TNF
 production. Two studies
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differ from a study from Franssen, who found that PR3- the country. Does cluster analysis suggest that further
ANCA were more activating than MPO-ANCA [81]; detailed epidemiologic analysis might lead to identifica-
however, this study was difficult to interpret, as the MPO- tion of a facilitating infection?
ANCA used were no more activating than normal con- Prof. Savage: Other than the association with nasal
trol IgG. If these effects are relevant to the presence or carriage of Staphylococcus aureus that I described, other
absence of granulomata, one would have to speculate searches for facilitating infections have not been produc-
that PR3-ANCA with the very lowest neutrophil-activat- tive. However, a systematic epidemiologic study might
ing potential are associated with granuloma formation. provide further insights.
It is not clear why MPO-ANCA are more activating Prof. Stephen Powis (Centre for Nephrology, Royal
than PR3-ANCA; the difference cannot be explained by Free and University College Medical School, London,
increased expression of MPO on the cell surface, as PR3 England): Have any family-based studies attempted to
is expressed on more cells than MPO. Neither can IgG quantify the overall genetic component of ANCA-asso-
subclasses account for the difference; IgG1 and IgG4 are ciated vasculitis?
the predominant isotypes in both MPO-ANCA and PR3- Prof. Savage: The literature contains a handful of
ANCA. Although IgG3 ANCA has been suggested as reports of both Wegener’s granulomatosis and micro-
more activating, PR3-ANCA contains more IgG3 than scopic polyangiitis occurring in sibling pairs or in a parent
does MPO-ANCA. and child. As yet, these kindreds have not been subjected
Dr. Jeremy Duffield (Department of Renal Medicine, to detailed genetic analysis.
Royal Infirmary, University of Edinburgh): You de- Prof. Charles Pusey (Renal Section, Imperial College,
scribed the well-recognized association between clinical London, England): I was struck by the marked rise in
infection and disease induction or relapse. One hypothe- the MPO-ANCA titer that occurred several weeks be-
sis is that the infection leads to release of pro-inflamma- fore the clinical relapse, and by the extent of interstitial
tory cytokines that might up-regulate the immune re- damage in the second renal biopsy. Do you think that
sponse. If your model of disease initiation is correct, some subclinical renal damage might have occurred be-
one might expect sterile inflammation, such as operative fore the relapse was diagnosed? Do you think that any
wounds or trauma, to lead to disease induction. Is there change in treatment is justified on the basis of a rising
any evidence for this? ANCA titer?
Prof. Savage: That’s a very interesting point. It has Prof. Savage: It is possible that continuation of low-
been recognized for 30 years that relapses of vasculitis dose azathioprine and prednisolone caused partial dis-
can follow an intercurrent infection. A systematic search ease suppression, so although clinically inactive by our
to determine whether sterile inflammation has a similar
criteria, there was continuing tissue injury. In retrospect,
effect would be valuable. I don’t know of such a study.
the rising ANCA titer might have indicated occult dis-Prof. Michael Dillon (Great Ormond Street Hospital
ease activity. As discussed, the predictive value of a risefor Children, London, England): This patient’s initial pre-
in ANCA titer for relapse was 57% in one study. Treatingsentation and subsequent relapse were preceded by upper
on the basis of changing serology alone, however, mightrespiratory tract symptoms. Kawasaki disease manifests
expose some patients to unnecessary risks from increasedevidence of an infective precipitant, and superantigens
immunosuppression.have been invoked. In addition, support exists for a super-
Prof. Alex Davison (St. James’s University Hospital,antigen role in Wegener’s granulomatosis [35]. Brogan
Leeds, England): I was very impressed that the secondet al, working in our department, similarly have demon-
biopsy showed a large amount of interstitial damage. Itstrated superantigen involvement in childhood vasculitides
suggested to me that something had been going on in[abstract; Brogan et al, Clin Exp Immunol 120(Suppl 1):
spite of your apparently very effective therapy. In view46, 2000]. What is your view about the potential superan-
of the fact that serology is not particularly helpful, whattigen etiology of vasculitic episodes?
is the place of a protocol biopsy to determine subsequentProf. Savage: If a link between Staphylococcus aureus
therapeutic management once remission is achieved?carriage in the nose and relapse of Wegener’s is proven,
Prof. Savage: We have used protocol biopsies at sixone hypothesis is that this is due to a superantigen. In
months in patients with Henoch-Scho¨nlein vasculitisaddition, three studies that have found expansions of
whom we have treated with immunosuppressive drugs.T-cells bearing particular V receptors in patients with
Therapy is then continued or discontinued dependingWegener’s granulomatosis and microscopic polyangiitis
on the results of the biopsy [84]. I think a protocol biopsy[35, 82, 83] might support a role for superantigens in
would be worth considering in ANCA-associated vascu-disease initiation.
litis, provided it was undertaken within the context of aDr. Alan Watson (City Hospital, Nottingham, En-
clinical trial. It also would help to address whether particu-gland): The patient was a poultry farmer and you alluded
to an increasing incidence of vasculitis in a rural area of lar subgroups of patients are more prone to continuing
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occult disease activity, for example, those who remain tivity in a patient who might have a relapse will guide
the decision to re-introduce therapy, and the type ofANCA-positive or who have a rising ANCA titer.
Dr. Neil Iggo (Royal Sussex County Hospital, Brigh- therapy can be guided by the severity of the relapse.
Prof. Peter Mathieson (Academic Renal Unit, Uni-ton, England): Of course we are concerned about the
toxicity of treatment, but we should not forget that until versity of Bristol, Southmead Hospital, Bristol, England):
Why is cyclophosphamide more effective at remissioncyclophosphamide was introduced, Wegener’s was an
almost universally fatal illness. Given that more than induction than azathioprine, yet, as shown by the CYCA-
ZAREM trial, it is no better than azathioprine for remis-50% of people who have a recurrence of ANCA develop
a relapse, and given that the CYCAZAREM trial has sion maintenance?
Prof. Savage: Cyclophosphamide induces remissionshown that 3 months and 12 months of cyclophospha-
mide are as safe or as toxic, depending on your point of in more than 90% of patients and in many patients in-
duces the ANCA to fall. When cyclophosphamide is dis-view, do you think that the time has come to organize
a trial of 3 months of initial treatment with cyclophospha- continued, the plasma cells can slowly become active
again, and azathioprine might be less effective at control-mide and then treat any serologic recurrence of ANCA
positivity with a further 3 months of cyclophosphamide ling these. It is clear that cyclophosphamide is not good
at establishing tolerance, because relapse is common andto see whether that approach could prevent relapse, and
to determine whether that regimen is safe? often associated with ANCA.
Dr. Harrington: Could you expand on the issue ofProf. Savage: I think that comes back to an earlier
question of whether we are missing ongoing tissue injury oral versus intravenous cyclophosphamide for the treat-
ment of Wegener’s?and whether a protocol renal biopsy would be justified.
Unless we can be sure that a rising ANCA titer correlates Prof. Savage: Pulses of intravenous cyclophospha-
mide have been used very effectively in the control of lu-with continuing occult disease activity, I would not re-
introduce cyclophosphamide. pus nephritis, and it was because of its effectiveness in
that setting that it was introduced for treatment of vascu-Dr. David Reaich (South Cleveland Hospital, Mid-
dlesborough, England): Please comment on the value of litis. The potential benefit of using intermittent pulses
of cyclophosphamide, whether given orally or intraven-renal biopsy. I was intrigued that you opted to biopsy
the patient on the second occasion when relapse was ously, is that the patient receives approximately one-half
the total dose of cyclophosphamide that would have beenalready apparent. You alluded to the difficulty in decid-
ing whether to re-introduce immunosuppression with the administered orally. Given the toxicity of cyclophos-
phamide, that might be very beneficial. The question isrising ANCA. Would it perhaps not be more appropriate
to perform a biopsy at that point to decide whether to whether intermittent pulses of cyclophosphamide are as
effective for induction of remission as daily oral cyclo-amplify the immunosuppression before the relapse?
Prof. Savage: The reason we did the second biopsy phosphamide. A recent meta-analysis (unpublished data)
suggested that they are, but at the expense of an in-was because the clinical symptoms were relatively mild:
the patient had a positive ANCA but had had a positive creased number of relapses. The CYCLOPS study, orga-
nized by the European Vasculitis Study Group, shouldANCA for some time; the CRP had increased, but only
to 37 mg/L, and she had recently had upper respiratory confirm or refute this.
Dr. John Bone (Royal Liverpool Hospital, Liverpool,tract infections; and the creatinine had risen modestly
with recrudescence of hematuria. The renal biopsy was England): Cyclophosphamide-based regimes carry a big
risk of side effects. Would it not be reasonable to reservevery helpful in confirming the clinical suspicion of relapse.
I think it would be difficult to justify a renal biopsy in cyclophosphamide for severe disease involving lung
hemorrhage and perhaps use mild regimes involving aza-the presence of recurrence of ANCA or a rising ANCA
titer unless a change was found in the urine sediment or thioprine from the outset for patients with less-systemic
disease?renal function.
Dr. Ian Roberts (Renal Pathologist, John Radcliffe Prof. Savage: I think there is a move to do just that
in patients with limited Wegener’s, for example, to useHospital, Oxford, England): As a pathologist, I am inter-
ested in knowing what impact disease activity in the renal methotrexate in preference to cyclosphamide in patients
without renal involvement. This has been tested by thebiopsy specimen has on the way you manage the patient,
and what drugs you give. EUVAS trial “NORAM,” which will report in 2001. Once
there is clinical evidence of systemic disease, even if thisProf. Savage: Let me give you two examples. Presence
of disease activity in a patient who is dialysis-dependent is mild without major tissue injury, it is important that
the disease be controlled quickly to limit tissue damageat presentation, providing there are some viable glomer-
uli left, is an indicator that full therapy will be useful, that and prevent progression. Cyclophosphamide is currently
the best drug we have to do this.is, cyclophosphamide, prednisolone, and either plasma
exchange or methylprednisolone. Presence of disease ac- Dr. Lynda Stuart (MRC Centre for Inflammation
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Research, Edinburgh University, Edinburgh): I was in- Wegener’s to relapse compared with patients who have
trigued by the fact that antigen-specific T-cells are pres- microscopic polyangiitis. Perhaps we should consider
ent in peripheral blood. Are any trials looking at T-cell- maintenance therapy for patients who are most likely to
specific treatment, such as antibodies against CD40 li- relapse. At present, I do not differentiate between PR3-
gand or CTLA4Ig? ANCA– and MPO-ANCA–positive microscopic polyan-
Prof. Savage: Martin Lockwood undertook studies giitis patients for the reasons discussed earlier.
using anti-T-cell therapies, anti-CD4 and -CD56, for Prof. Eberhardt Ritz (Department of Internal Medi-
treatment of vasculitis. In many patients those therapies cine, University of Heidelberg, Heidelberg, Germany):
were very valuable for inducing and maintaining remis- Stegmar et al reported that trimethoprim-sulfamethoxa-
sion. Anti-CD40 ligand antibodies have been associated zole given prophylactically reduces the number of recur-
with a thrombotic risk (unpublished data), so they might rences [36], and I wonder why this is not prescribed rou-
be hazardous in vasculitis, which carries an increased tinely. Do you have experience to the contrary, or is
incidence of thrombotic events. there a consensus in the vasculitis community that the
Dr. Gill Gaskin (Imperial College School of Medi- data are not sufficiently solid?
cine, London): Would you treat all generalized ANCA- Prof. Savage: There was a 20% incidence of side ef-
associated vasculitis in the same way, irrespective of the fects in the study you cite, and this might be the reason
phenotype or the ANCA specificity? why trimethoprim-sulfamethoxazole is not used rou-
Prof. Savage: I like to tailor immunosuppression to tinely. We do not know whether the effect was due to
severity of the disease. Our practice is guided by this prin- eradication of nasal carriage of Staphylococcus aureus
ciple. For example, we did not prescribe plasma ex- or another antibacterial or immunosuppressive effect of
change or methylprednisolone for the patient we have the drug. If an association between S. aureus nasal car-
discussed. However, if there had been pulmonary hemor- riage and increased likelihood of relapse is confirmed,
rhage, we would have had no hesitation in doing so. I it might be possible to eradicate S. aureus using less-
would like a greater choice of therapies to allow us to toxic agents such as mupirocin.
adjust treatment to suit the age of the patient, the pres-
ence of other co-morbidity, as well as the severity and NOTE ADDED IN PROOF
the type of organ involvement. As to whether I would treat
The following articles, quoted in text, are now in press:patients with PR3-ANCA or MPO-ANCA differently, I Ben-Smith A, Dove SK, Martin A, Wakelam MJO, Savage COS:
have already alluded to a greater neutrophil activating Anti-neutrophil cytoplasm autoantibodies from patients with systemic
vasculitis activate neutrophils via distinct signalling cascades comparedcapacity with IgG from MPO-ANCA-positive patients
to conventional Fc	 receptor ligation. Blood, in press[80]. Despite this, several studies, including those of
De Groot K, Adu D, Savage COS: The value of pulse cyclophos-
Franssen and Geffriaud-Ricouard [85, 86], have not phamide in ANCA-associated vasculitis. Meta-analysis and critical re-
view. Nephrol Dial Transplant, in pressshown any difference in outcomes between either anti-
body group. Some, but not all the studies, have suggested
that PR3-ANCA is associated with a higher relapse rate ACKNOWLEDGMENTS
than is MPO-ANCA. However, several studies, includ- Dr. A.J. Howie provided the photographs of the renal biopsies,
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Hewins helped with preparing the manuscript.relapse in Wegener’s compared with microscopic polyan-
giitis (abstract; Jayne et al, J Am Soc Nephrol 10:105A,
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